Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20053291 | 0.86 | KDM4E (0.35) | KDM4ESMN1; SMN2ALDH1A1LMNAAPEX1 | |
| SCHEMBL15298472 | 0.82 | KDM4E (0.41) | KDM4ESMN1; SMN2APEX1BLMPOLB | |
| SCHEMBL20053362 | 0.79 | SMN1; SMN2 (0.37) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL23100380 | 0.75 | CHRNB2 (0.42) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL20053361 | 0.73 | CHRNB2 (0.50) | SMN1; SMN2ALDH1A1LMNAMAPTBLM | |
| SCHEMBL14592906 | 0.73 | KDM4E (0.40) | KDM4ESMN1; SMN2APEX1BLMPOLB | |
| SCHEMBL19573406 | 0.71 | KDM4E (0.43) | KDM4ESMN1; SMN2ALDH1A1MAPTPOLB | |
| SCHEMBL14754887 | 0.71 | — | — | |
| SCHEMBL3716684 | 0.71 | KDM4E (0.41) | KDM4ESMN1; SMN2ALDH1A1LMNAAPEX1 | |
| SCHEMBL22305211 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259818-B2 | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259818-B2 | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors | PIK3CD, PIK3CA, PIK3CB | KDM4E 727/4885SMN1; SMN2 4575/4885ALDH1A1 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.